The status for each dose of Wegovy^® is now reflected on the FDA shortage website as, “Available.”

We are running our manufacturing lines 24 hours a day, seven days a week, manufacturing more Wegovy^® than ever before.  Our intentional approach to gradually increase supply into the U.S. market is working and all of the dose strengths of Wegovy^® are being shipped regularly to wholesalers.

We will continue to prioritize continuity of care for patients, closely monitoring market dynamics and prescribing trends along the way. It is important to note that even when a medication is available, patients may not always be able to immediately fill their prescription at a particular pharmacy. Patients may experience variability at a particular pharmacy location regardless of whether a drug is in shortage.

Increasing our manufacturing capacity is a key factor in our ability to produce more medicines and we continue to expand our global production capacity, which has been running 24 hours a day, seven days a week.

We understand how frustrating this is for the communities we serve and recognize how important it is for people currently using Wegovy^® to continue their weight management journey. We recommend that those who experience challenges filling their prescriptions speak with a healthcare professional about the best approach to their treatment, so this does not halt their pursuit of obesity care.

Although Wegovy^® and Ozempic^® both contain semaglutide, they are different products with different indications, dosages, prescribing information, and titration schedules, as approved by the FDA. Each medication has a unique safety and efficacy profile, which is detailed in its respective product label. The products are not interchangeable. We support our medicines being prescribed to patients who meet the indicated criteria and only promote the FDA-approved indications of our medicines for appropriate patients. Click here to read more about our commitment to the responsible use of our medicines.

At this time, we do not recommend switching to Saxenda^® as a viable alternate treatment, as we cannot guarantee supply to match the continuous rising demand for weight management medications.

Novo Nordisk is the only company with FDA-approved, prescription-only semaglutide medicines: Wegovy^®, Ozempic^®, and Rybelsus^®. No other FDA-approved generic or alternative semaglutide medicines exist. We are deeply concerned about companies promoting and selling compounded, non-FDA approved knock-off versions of "semaglutide" and sources spreading misinformation about GLP-1 RAs to the public. These knock-off medicines are not approved or reviewed by the FDA for safety, quality, and effectiveness. Patients have reported harm after taking these products and there is substantial evidence that copycat “semaglutide” presents significant and serious safety and health risks.

In addition, the FDA shared safety information on compounded semaglutide on their website. For more information, click here: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA.

Novo Nordisk is taking robust and proactive measures to protect patients and warn them about the dangers of non-FDA approved knock-off versions of "semaglutide," including correcting misinformation, educating communities, taking legal action, conducting ongoing testing of samples and most recently, nominating semaglutide to the FDA’s lists of medicines that are too complex to compound (“DDC Lists”). Our ongoing efforts, detailed on semaglutide.com, are geared toward protecting patients and ensuring they have access to safe and effective FDA-approved medicines.

Novo Nordisk is not supplying any telehealth companies with Wegovy^®. Any healthcare professionals prescribing Wegovy^® through telehealth companies will face the same supply challenges as all other healthcare professionals and patients across the U.S.

We see the growing trend of weight-management telehealth providers and have heard media reports that some telehealth providers are not providing sufficient clinical evaluations prior to prescribing semaglutide containing medicines, including Wegovy^® and Ozempic^®. Novo Nordisk medicines should only be prescribed after a close consultation between a licensed healthcare professional and a patient – considering the medication’s benefits and risks for that individual patient – and should only be taken under the supervision of a licensed healthcare professional.